Regeneron Pharmaceuticals Faces Securities Class Action After 9 Billion Value Loss
Published on January 23, 2025
Regeneron Pharmaceuticals, Inc. (REGN) is currently facing a securities class action following a significant loss in value. The company recently reported its Q3 2024 earnings, which resulted in a loss of 9 billion in market value. The law firm Hagens Berman has filed the class action lawsuit on behalf of investors who have suffered substantial losses. Regeneron Pharmaceuticals, known for its ability to develop new medicines, now faces legal challenges that could impact its future performance. Investors with significant losses have the opportunity to lead the class action lawsuit. For more information and expert analysis on the future movement of REGN stocks, it is recommended to consult the professionals at Stocks Prognosis.
Investor opinions & comments
To leave a comment, you need to Login or Register.
There are no comments yet. Be the first to leave one!